# Arsenal Biosciences, Inc.: Phase 2 study closed enrollment, 37 enrolled (Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence)

**Score:** 90/100

| Field | Value |
|---|---|
| Sponsor | Arsenal Biosciences, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) |
| NCT ID | NCT06245915 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Advanced/Metastatic Clear Cell Renal Cell Carcinoma; Recurrence |
| Intervention types | biological |
| Target enrollment | 37 |
| Site countries | United States |
| Posted | 2024-02-07 |
| Planned start | 2024-02-26 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06245915). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.